Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | GLB1 | P16278 | 1/20 | 0.37 |
| ▸ | GUSB | P08236 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | EBP | Q15125 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25821419 | 1.00 | GBA1 (0.41) | GBA1GLB1GUSBSIGMAR1EBP | |
| SCHEMBL24773751 | 0.92 | GBA1 (0.45) | GBA1GLB1GUSBSIGMAR1EBP | |
| SCHEMBL27097531 | 0.85 | GLB1 (0.54) | GBA1GLB1GUSBSIGMAR1EBP | |
| SCHEMBL27097593 | 0.85 | GLB1 (0.54) | GBA1GLB1GUSBSIGMAR1EBP | |
| SCHEMBL17918965 | 0.84 | GNAI3 (0.43) | SIGMAR1DRD2DRD3DRD1DRD4 | |
| SCHEMBL17918966 | 0.84 | GNAI3 (0.43) | GBA1GLB1SIGMAR1DRD2DRD3 | |
| SCHEMBL25610535 | 0.84 | GBA1 (0.41) | GBA1GLB1SIGMAR1EBPDRD2 | |
| SCHEMBL12717521 | 0.84 | GBA1 (0.41) | GBA1GLB1GUSBSIGMAR1EBP | |
| SCHEMBL23875383 | 0.81 | GNAI3 (0.53) | DRD2 | |
| SCHEMBL20863111 | 0.81 | GUSB (0.57) | GBA1GLB1GUSBSIGMAR1EBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | IKZF2, RPL6, HNRNPR | GBA1 3008/4885GLB1 2894/4885GUSB 3843/4885 |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | IKZF2, RPL6, HNRNPR | GBA1 3008/4885GLB1 2894/4885GUSB 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.